AI Assistant
Blog
Pricing
Log In
Sign Up
Brentuximab vedotin (BV) was effective against <i>ATIC</i>-<i>ALK</i> positive ALCL during a follow-up of cytopenia in an aged patient
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
